Whan In Pharm Co.,Ltd.

KSE 016580.KS

Whan In Pharm Co.,Ltd. EBIT Margin for the year ending December 31, 2023: 15.11%

Whan In Pharm Co.,Ltd. EBIT Margin is 15.11% for the year ending December 31, 2023, a -0.03% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Whan In Pharm Co.,Ltd. EBIT Margin for the year ending December 31, 2022 was 15.11%, a -20.98% change year over year.
Whan In Pharm Co.,Ltd. EBIT Margin for the year ending December 31, 2021 was 19.12%, a 15.54% change year over year.
Whan In Pharm Co.,Ltd. EBIT Margin for the year ending December 31, 2020 was 16.55%, a -6.72% change year over year.
Whan In Pharm Co.,Ltd. EBIT Margin for the year ending December 31, 2019 was 17.74%, a -6.41% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

KSE: 016580.KS

Whan In Pharm Co.,Ltd.

CEO	Mr. Wonbum Lee
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	Whanin Building, 11
Employees	582
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Whan In Pharm Co.,Ltd., a pharmaceutical company, develops, manufactures, markets, and sells therapeutic products in South Korea. It offers anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, cardiovascular, gastrointestinal, antibiotics, antiviral agents, antihistamines, anti-inflammatory and analgesics, metabolic disorders, respiratory, central nervous system, other drug products. The company was founded in 1978 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years